Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Yo Duble d,
From the Hong Kong trial with interferon B amongst triple combo treatment:
The significantly better clinical and virological response is also reflected in the shorter median hospital stay in the combination group than in the control group (9·0 days [7·0–13·0] vs 14·5 days [9·3–16·0]; HR 2·72 [1·2–6·13], p=0·016).
That’s an improvement of 5.5 days!. I’ll see your four and raise you:).
DubleD - my apologies yes early trials have suggested remdesivir can reduce recovery time by up to 4 days.
I will be interested to see if that number gets adjusted once proper trials have been conducted.
Time will tell.
SNG001 could yet be used to compliment remdesivir with remdesivir only being used for patients at later stages of the infection.
Ghia - remdesivir offers a 4 day improvement
£12 what?....a share!?
Just a little optimistic to say the least if that's what you are saying, or what timeframes are you referring to?
Yes and its *******s - Between Feb 6, 2020, and March 12, 2020, 237 patients were enrolled and randomly assigned to a treatment group (158 to remdesivir and 79 to placebo); one patient in the placebo group who withdrew after randomisation was not included in the ITT population. Remdesivir use was not associated with a difference in time to clinical improvement (hazard ratio 1•23 [95% CI 0•87–1•75]). Although not statistically significant, patients receiving remdesivir had a numerically faster time to clinical improvement than those receiving placebo among patients with symptom duration of 10 days or less (hazard ratio 1•52 [0•95–2•43]). Adverse events were reported in 102 (66%) of 155 remdesivir recipients versus 50 (64%) of 78 placebo recipients. Remdesivir was stopped early because of adverse events in 18 (12%) patients versus four (5%) patients who stopped placebo early.
Im glad its making people who take it feel better and recover. One day there will be a better treatment that people will take, a treatment so good that they they won't fall so ill to start with.
I’m seeing words such as blockbuster being bandied about referring to results. Suggestions that early signs are not great etc.
We probably need to do a bit of expectation management and this post is aimed at that.
We are aiming to recruit 100 patients, for arguments sake let’s use a 1% mortality rate for Covid that will mean sadly 1 person from the trial cohort will not make it.
That means the 99 remaining patients will pull through.
Obviously this means it’s not going to be clear cut as those on the drug survived and those not on the drug did not.
Once the data is analysed we will be looking for trends such as the drug reduced recovery time by X days or the lasting damage caused by the virus was less when on the drug, using the drug prevented the requirement for more invasive treatment.
Throw in the double blind nature of the data it will be incredibly hard to predict anything at this stage.
Remdesivir offers a 2day improvement and look at the press it has got globally.
We are looking for small margins here we’d all do well to remember that.
There is a treatment. Our lovely health minister shouted from the roof tops about it earlier. It’s called Remdesivir.
£12 min. Gl g9
Notnow20 ,
During a double blinded trial , interim analysis are conducted by the DSMB ....
The question is what are people’s predictions if results are successful? Seems like no news can lift off this range at the moment. I’m 20% down at the moment on 400k shares. Luckily some other shares have more than consolidated the loss but the SP needs to go some for me to get in the blue. Hard to see it re-rate but I’m very much hoping it will! GLA
In the news articles today the ceo stated this stops the patients progressing into the second week of deterioration. Correct me if I'm wrong but that was there. I'm in this massively. I'm seeing some turbulence. But ultimately the home trials will be a gold standard proven job done let's shout about it treatment. Plenty of things around in other countries non proven saying great things etc. And also some loosely indicating otherwise. I'm holding long. Nothing else is this far progressed In a gold standard trial that other countries have loosely indicated as useful.
I don’t think they know anymore than us on the trials they can’t it’s not possible. What I do think is there is instruction to offload at given price points by the II which is what has created this coiled spring on the chart. I believe this unloading is what is holding the SP back, I have seen it before and given where the company is heading and the positive news flow 50p does not feel right. There is also a left field theory that there is a buyer operating in the trading range as what has been unloaded is a lot for PI to absorb. What I do think is cone August this will all be irrelevent. Patience required.
If it drops 30p tomo it doesn,t matter...none of the share price matters up or down...Its just a case of HOLD until the end...If it turns out to be a winner,the share price will then reflect that,What happens between now and then is irrelevant IMO
Thanks notnow, so we have software in the loop, makes sense.
Crookie36340
DSMB ....
https://www.fda.gov/media/75398/download
Notnow - you can look on the positive side to every bit of news. There must come a time though when you have to look at your investment and decide if you made the right decision. We are all here to make money. And just incase you ve not noticed. The sp isn’t going anywhere but down.
The II know no more than us but the ability to sell and buy their holdings is not transparent, the SP is disjointed IMO. This will rerate, should be 70/80p not 50p IMO. Too many shares on offer, being well managed for something.
Doesn't need to be blockbuster though. Any efficacy would be a positive from the hospital trials. The real benefit hopefully will come from the home trials. Thats where the intervention is most needed as it will hopefully stop virus progression to hospitilisation and ventilation.
Guessing if they were blockbuster then they wouldn't be struggling for the last 2 patients with 4000 cases confirmed today. I wish I wasnt even considering this. Down the line it's going to be useful. But seemingly his video to me inferred that the hospital patients weren't in the best shape.
Nolupus what’s your thinking on the COPD announcement? Given the discussion?
Oilornothing ,
Sometimes it's better to say nothing than prove to everyone just how ´ intelligent you really are :-)
Given Covid 19 shuts down your Interferon response, I think it’s a given you would be best to take it early.
and another thing. I believe this is only going to benefit us because if the results of the hospital trials are not blockbuster, as some suspect may be the case, they will keep the data to themselves and not release to the market until after the home trials. If they are blockbuster results we will know immediatly. Win win imo.
I understand your argument Nolupus, and you could be right. But the unblinding is a very big deal because we are going to get data from the unblinding, the curtain is coming down. I would be surprised if there is no efficacy in the COPD trial. Does anyone know how the double blind works? In that does someone know how it is going or is it all unravelled at the end? Because if someone does know then that would be a big signal to me, otherwise wtf are we doing waiting everyone’s time.